极度早产婴儿的自发性肠道穿孔,这些婴儿暴露于早期低剂量皮
Gilles Cambonie1,2, Anais Jouffrey1, Benoit Tessier3,4
1Department of Neonatal Medicine, Pediatric Intensive Care and Pediatric Emergency Transport Service, Arnaud de Villeneuve Hospital, Montpellier University Hospital Centre, University of Montpellier, Montpellier, France.
Acta paediatrica (Oslo, Norway : 1992)
|June 11, 2025
概括
在早产婴儿 (<28周) 中,早期的皮松和布洛芬治疗增加了自发肠孔 (SIP) 的风险. 这种组合疗法需要仔细考虑,因为极度早产新生儿的潜在不良结果.
科学领域:
- 新生儿科学 新生儿科学
- 儿科手术 儿科手术
- 药理学 药理学是指药理学的学科.
背景情况:
- 支气管肺功能障碍症 (BPD) 和持续性动脉管 (PDA) 在婴儿<28周妊娠年龄 (GA) 中很常见.
- 早期低剂量皮醇 (ELH) 用于预防BPD,而布洛芬用于治疗PDA.
- 对于ELH和易布洛芬对自发性肠穿孔 (SIP) 风险的联合作用尚未完全理解.
研究的目的:
- 为了评估SIP的发病率在28周GA暴露于ELH的婴儿中.
- 评估暴露于ELH和PDA早期布洛芬治疗的婴儿SIP的风险.
主要方法:
- 观察性研究比较暴露和未暴露于ELH的婴儿.
- 关键新生儿因素的匹配 (分娩方式,GA,出生体重,性别).
- 多变量物流回归分析以确定SIP的风险因素.
主要成果:
- 暴露于ELH的婴儿有较高的SIP率 (8.1%与2.9%相比).
- 同时使用ELH和易布洛芬治疗进一步增加了SIP风险 (11.8%对3.8%).
- 后勤回归证实了ELH和伊布罗芬联合治疗增加了SIP风险 (OR 2.93 [1.24-6.93]).
结论:
- 早期同时使用ELH和布洛芬的治疗与SIP的风险显著增加有关.
- 这一发现凸显了这种组合治疗对极度早产婴儿的潜在安全问题.
- 可能需要进一步的研究来优化BPD和PDA的治疗策略,同时最大限度地降低SIP风险.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
01:22Esophageal Perforation-I: Introduction
68
Esophageal perforation is a severe medical condition characterized by a breach in the integrity of the esophageal wall. This breach can occur due to various factors such as trauma, medical procedures, or underlying diseases. When the esophageal wall is compromised, it allows food, fluids, and digestive juices into the chest cavity or adjacent structures, leading to potential complications and health risks.
The location of esophageal perforation can vary, occurring anywhere along the esophagus....
The location of esophageal perforation can vary, occurring anywhere along the esophagus....
68
01:28Esophageal Perforation-II: Clinical Manifestations and Management
45
Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
Clinical Manifestations:
45
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
148
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
148